IMMU Stock Overview
A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Mendus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.17 |
| 52 Week High | SEK 11.26 |
| 52 Week Low | SEK 7.10 |
| Beta | 0.81 |
| 1 Month Change | -3.17% |
| 3 Month Change | -0.54% |
| 1 Year Change | -21.94% |
| 3 Year Change | -90.47% |
| 5 Year Change | -96.19% |
| Change since IPO | -95.20% |
Recent News & Updates
Recent updates
Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate
Aug 31
We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate
Feb 20Mendus (STO:IMMU) Is Making Moderate Use Of Debt
Mar 28Is Mendus (STO:IMMU) Using Debt Sensibly?
Dec 01Is Mendus (STO:IMMU) Using Debt Sensibly?
Aug 10Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?
May 10Is Immunicum (STO:IMMU) Using Too Much Debt?
Jan 31Shareholder Returns
| IMMU | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.5% | 0.5% | -0.1% |
| 1Y | -21.9% | 12.2% | 3.7% |
Return vs Industry: IMMU underperformed the Swedish Biotechs industry which returned 12.2% over the past year.
Return vs Market: IMMU underperformed the Swedish Market which returned 3.7% over the past year.
Price Volatility
| IMMU volatility | |
|---|---|
| IMMU Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: IMMU's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: IMMU's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 28 | Erik Manting | www.mendus.com |
Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which completed Phase I clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a preclinical study for NK cell-based therapies.
Mendus AB (publ) Fundamentals Summary
| IMMU fundamental statistics | |
|---|---|
| Market cap | SEK 443.16m |
| Earnings (TTM) | -SEK 138.05m |
| Revenue (TTM) | SEK 6.94m |
59.2x
P/S Ratio-3.0x
P/E RatioIs IMMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMU income statement (TTM) | |
|---|---|
| Revenue | SEK 6.94m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.94m |
| Other Expenses | SEK 144.99m |
| Earnings | -SEK 138.05m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -2.74 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,988.03% |
| Debt/Equity Ratio | 0.1% |
How did IMMU perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 18:53 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mendus AB (publ) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |
| Stefan Wård | Pareto Securities |
| Chien-Hsun Lee | Pareto Securities |